Friday, January 31, 2025 | 07:59 PM ISTEN Hindi
Business Standard
Notification Icon
userprofile IconSearch

Strong US sales momentum may drive further gains for Zydus Lifesciences

Market share gains in the Indian market and margin expansion are other positives

Cadila Healthcare changes name to Zydus Lifesciences Limited
Premium

The y-o-y growth was driven by market share gains in key therapies such as cardiovascular, gastrointestinal, respiratory and gynecology

Ram Prasad Sahu
The stock of pharmaceutical major Zydus Lifesciences is up about 10 per cent from its low towards the end of November, even after considering the correction seen in the past few sessions. Brokerages are positive on the stock, given traction for its key products in the US market, new limited-competition drug launches, regulatory clearance for the Moraiya facility and market share gains in the domestic market.
 
The near-term trigger has been the launch of the generic version of Trokendi in the US. The drug used in treating migraines has been launched by Zydus in three strengths with a market size of

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in